Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.33 USD
Change Today +0.07 / 1.64%
Volume 6.0K
WGBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

wafergen bio-systems inc (WGBS) Snapshot

Open
$4.20
Previous Close
$4.26
Day High
$4.37
Day Low
$4.20
52 Week High
07/1/14 - $25.00
52 Week Low
12/31/14 - $2.85
Market Cap
24.5M
Average Volume 10 Days
45.9K
EPS TTM
$-4.75
Shares Outstanding
5.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WAFERGEN BIO-SYSTEMS INC (WGBS)

Related News

No related news articles were found.

wafergen bio-systems inc (WGBS) Related Businessweek News

No Related Businessweek News Found

wafergen bio-systems inc (WGBS) Details

WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for gene expression quantification, genotyping, and stem cell research for the life sciences and pharmaceutical drug discovery industries in the United States, Canada, Europe, and the Asia Pacific. The company offers SmartChip Real-Time PCR system, which provides a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of real-time polymerase chain reaction (PCR). Its SmartChip Real-Time PCR system consists of two instrumentation components comprising a SmartChip MultiSample NanoDispenser for applying sample, assay, and reaction mix to the SmartChip Panels; and a SmartChip Cycler for thermal cycling and collecting data from the real-time PCR assays. The company also provides SmartChip Target Enrichment system for performing a sample preparation step prior to targeted next-generation sequencing (NGS); and Apollo 324TM library preparation System, a walk-away automation platform that offers DNA, RNA-Seq, and ChIP-Seq library preparation kits for analysis on NGS platforms. The company focuses on providing its products to researchers who perform genetic analysis and cell biology, primarily at pharmaceutical and biotech companies, academic and private research centers, and diagnostics companies involved in biomarker discovery and genetic research. WaferGen Bio-systems, Inc. was founded in 2002 and is headquartered in Fremont, California.

45 Employees
Last Reported Date: 03/17/15
Founded in 2002

wafergen bio-systems inc (WGBS) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $720.0K
Compensation as of Fiscal Year 2013.

wafergen bio-systems inc (WGBS) Key Developments

WaferGen Bio-systems, Inc. Announces Research Collaboration with Genentech Initiating its Early Access Program for Single Cell Genomics Technology

WaferGen Bio-systems, Inc. announced that the Company has signed a research collaboration with Genentech to evaluate and apply WaferGen's SmartChipTM platform in single cell sequencing. The joint work is aimed at validating the utility of the SmartChipTM technology for isolating single cells from various tissues and preparing libraries for Next-Generation Sequencing (NGS). Â Genentech represents WaferGen's initial partner in WaferGen's single cell genomics technology-focused Early Access Program. WaferGen successfully completed separate proof-of-concept studies related to isolating single cells with the SmartChipTM earlier this year with both the Broad Institute and BGI. At the throughput level scalable to several thousand cells per sample, the cell's genetic composition was successfully analyzed via the NGS method, thereby demonstrating increased discovery potential in a single workflow. WaferGen continues to believe that the SmartChipTM technology will be able to yield a 50-fold increase in the production of single cells per chip versus current technologies at a fraction of the per cell cost.

WaferGen Bio-Systems, Inc. Announces an Industrial Partnership with Procter & Gamble

WaferGen Bio-systems, Inc. announced an industrial partnership with Procter & Gamble whereby Procter & Gamble will utilize WaferGen's SmartChip MyDesign quantitative PCR System to conduct various gene expression and other studies. As the amount of genomics data increases with the use of Next Generation Sequencing and microarrays, the need for high-throughput target validation becomes more acute. WaferGen's SmartChip platform offers two products that enhance these efforts, SmartChip MyDesign for qPCR and SmartChip TE for NGS sample preparation.

WaferGen Bio-systems, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015

WaferGen Bio-systems, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $1,611,720 against $490,465 a year ago. The increase is primarily due to an increase in SmartChip revenue of $0.6 million, plus Apollo revenue of $0.5 million compared to none in 2013. Operating loss was $3,518,046 against $2,134,113 a year ago. Net loss before provision for income taxes was $3,263,301 against income of $1,489,875 a year ago. Net loss attributable to common stockholders was $3,263,301 against income of $4,385,275 a year ago. Net loss per share basic and diluted was $0.58 against diluted earnings per share of $2.46 a year ago. For the year, the company reported total revenues of $6,001,342 against $1,304,747 a year ago. This growth was primarily driven by an increase in product revenue of $4.7 million, or 550%, to $5.5 million. Operating loss was $12,449,715 against $9,922,443 a year ago. Net loss before provision for income taxes was $10,689,763 against $16,259,931 a year ago. Net loss attributable to common stockholders was $10,692,863 against $17,712,066 a year ago. Net loss per share basic and diluted was $4.17 against $58.16 a year ago. The decrease in net loss was primarily due to the increase in revenue and the absence of one-time charges related to corporate restructuring incurred in the third quarter of 2013. The company currently expects full year 2015 revenue of $8.0 million to $8.5 million, which excludes revenue from single cell products, presently being developed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WGBS:US $4.33 USD +0.07

WGBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.78 USD -0.02
Exiqon A/S kr11.00 DKK +0.20
NanoString Technologies Inc $12.67 USD +0.73
Pacific Biosciences of California Inc $5.67 USD +0.51
Sequenom Inc $4.59 USD +0.15
View Industry Companies
 

Industry Analysis

WGBS

Industry Average

Valuation WGBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WAFERGEN BIO-SYSTEMS INC, please visit www.wafergen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.